Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
Eirini ZacharopoulouEleni OrfanoudakiMaria TzouvalaGeorge TriboniasGeorgios KokkotisVassiliki KitsouFoteini AlmpaniAggeliki ChristidouNikolaos ViazisGerassimos J MantzarisMaria TsafaridouKonstantinos KarmirisAngeliki TheodoropoulouEvgenia PapathanasiouEvanthia ZampeliSpyridon MichopoulosStefanos TigkasGeorgios MichalopoulosEfrossini LaoudiPantelis KaratzasIordanis MylonasNikolaos KyriakosChristos LiatsosTheodora KafetziGeorgios TheocharisStyliani TakaKonstantina PanagiotopoulouIoannis E KoutroubakisGiorgos BamiasPublished in: Inflammatory bowel diseases (2022)
Patients with IBD have impaired antibody responses to anti-SARS-CoV-2 vaccination, particularly those receiving viral vector vaccines and those on anti-TNFα treatment. Older age also hampers antibody production after vaccination. For those low-response groups, administration of accelerated or prioritized booster vaccination may be considered.